News and announcements from HANetf.

Stay up to date with the latest commentary on the ETF marketplace, stock stories and news here.

Healthcare Innovation ETF benefits from healthcare changes linked to COVID-19

21 September, 2020

Constituents of the HAN-GINS Indxx Healthcare Innovation UCITS ETF (WELL) continue to work at the forefront of the COVID-19 pandemic. Biotech constituents of the WELL innovative healthcare ETF, are leading vaccine research, as well as medical device constituents being amongst the biggest suppliers of PPE materials, ventilators and other respiratory equipment.

WELL healthcare ETF constituents continuing to benefits from COVID-19 requirements and healthcare changes, with Biological Engineering (Biotech), Robotics, and Healthcare Tracker constituents also being key contributors to its recent strong performance, gaining 1.03% in August, 7.33% in July and for the year it is up 32.46%. Past performance is no guarantee of future performance. When you invest in ETFs your capital is at risk.

The standout August constituent performers included iRhythm Technologies, Inc (Healthcare Trackers) 76.88% and Silk Road Medical, Inc (Medical Devices) 31.25%. The best performers in July were Seegene, Inc. (Medical Devices) 133.07%; Livongo Health, Inc. (Healthcare Tracker) 69.24% and Hansa Biopharma (Biological Engineering) up 53.53%[1].

The healthcare industry is increasingly using remote technology such as telemedicine, tracking devices, the cloud and robotics. Medical devices that can enhance such needs are increasingly in demand. Most recently, Google Cloud invested $100mn in Amwell, one of the largest telehealth providers. This follows news that its largest competitor, Teladoc, merged with Livongo, one of our holding, for $18.5 billion [2].

Anthony Ginsberg, Co-creator of the HAN-GINs Indxx Healthcare Innovation ETF (WELL) says: “As patients increasingly seek to avoid in-person medical help at hospitals and clinics, such remote tools facilitating virtual visits has skyrocketed in recent months. COVID-19 supply constraints are providing a boom to medical device and product manufacturers, particularly those focused on PPE & devices related to the pandemic (e.g. gloves, masks, respirators, ventilators). With the US Government’s Medicare insurance programme now reimbursing most telehealth services - this ensures remote/virtual medical care will become increasingly the norm for those preferring the convenience of home visits for regular check-ups where possible. Post-COVID, analysts expect hospitals to shift a larger volume of patient care to telehealth. We expect digital health technologies to see accelerated adoption.

“Digital pharmacies should deliver opportunities for investors, and major ecommerce companies will likely speed up entry into the health-care marketplace. In the U.S., the telehealth market now has an anticipated five-year compound annual growth rate of 38.2 percent.3 This equates to a staggering seven-fold increase by 2025. Furthermore, Telehealth, is anticipated to rise 64.3% in 2020, according to a recent Frost & Sullivan report.[4]

“This is an exciting time to be invested in healthcare innovation.”

The WELL innovative healthcare ETF is a UCITS compliant Exchange Traded Fund which is listed on the LSE, XETRA, SIX and Borsa Italiana.  It tracks the Indxx Advanced Life Sciences & Smart Healthcare Thematic Index (Net Total Return), an index designed to measure the performance of large, mid and small-capitalisation companies primarily listed on an exchange in Developed and Emerging Markets that are involved in the Advanced Life Sciences & Smart Healthcare sector.

Past performance is no guarantee of future performance. When you invest in ETFs your capital is at risk.

Read the September Healthcare Innovation Report.

Tell us how we can help